Related Experiment Videos
Iron management: innovative solutions to persistent challenges--focus on Ferrlecit.
S Vogel1, S Schweitzer, S Seiler
1Renal Replacement Therapies, Encino, Calif., USA.
ANNA Journal
|April 25, 2000
Summary
Sodium ferric gluconate offers an effective intravenous treatment for anemia in end-stage renal disease (ESRD) patients, overcoming oral iron limitations. Clinical data show an excellent safety and efficacy profile for this new iron supplement.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Anemia is a common complication in end-stage renal disease (ESRD).
- Oral iron supplements have limitations in managing anemia for ESRD patients.
- Intravenous (IV) iron therapies are an alternative treatment option.
Purpose of the Study:
- To discuss the role of sodium ferric gluconate in sucrose injection (Ferrlecit) for treating anemia in ESRD patients.
- To review the safety and efficacy of newly approved IV iron supplements.
- To explore optimal dosing and administration protocols for sodium ferric gluconate.
Main Methods:
- Presentations at a symposium focused on iron management in ESRD.
- Review of clinical trial data for sodium ferric gluconate.
- Discussion of iron metabolism and U.S. labeling requirements.
- Sharing of clinical experience and an experimental dosing protocol.
Main Results:
- Sodium ferric gluconate demonstrated an excellent safety and efficacy profile in clinical trials.
- The symposium highlighted sodium ferric gluconate as a new tool for iron management in ESRD.
- An experimental dosing and monitoring protocol was presented.
Conclusions:
- Sodium ferric gluconate is an important new therapeutic option for managing anemia in ESRD patients.
- It addresses the challenges and limitations associated with traditional oral iron therapy.
- Further clinical experience and protocol refinement are suggested.